Literature DB >> 17784888

A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome.

Matthew E Nielsen1, Ganesh S Palapattu, Pierre I Karakiewicz, Yair Lotan, Patrick J Bastian, Seth P Lerner, Arthur I Sagalowsky, Mark P Schoenberg, Shahrokh F Shariat.   

Abstract

OBJECTIVE: To examine the association between the interval from the last transurethral resection (TUR) to radical cystectomy (RC) and bladder cancer-specific outcome, as the decision to proceed to RC for an individual patient is complex, and recent reports suggest an interval from diagnosis to RC of >3 months is associated with adverse outcomes. PATIENTS AND METHODS: The records of 592 patients who had RC were reviewed; the interval from the last TUR was analysed as both a continuous and categorical variable (<3 vs >/=3 months). Logistic regression and survival analyses were used to evaluate the association between the interval to RC with pathological characteristics and clinical outcomes.
RESULTS: The mean (sd) actuarial cancer-specific survival was 70.5 (2.3)% and 60.7 (3.2)% at 3 and 7 years, respectively. Overall, the median (range) time from TUR to RC was 1.8 (0.3-11.6) months. The interval to RC analysed as a continuous or categorical variable was not associated with extravesical or nodal disease, lymph node metastases, disease recurrence, overall or cancer-specific survival. The results were similar in the subgroup of 320 patients (54%) with clinically muscle-invasive disease.
CONCLUSIONS: These results suggest that a reasonable delay from the last TUR to RC is not independently associated with stage progression or with decreased recurrence-free or disease-specific survival. These findings might have important implications for trial design in the ongoing evaluation of neoadjuvant regimens. Nevertheless, we see no reason to advocate anything less than the timely consideration of definitive treatment for patients with high-risk bladder cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17784888     DOI: 10.1111/j.1464-410X.2007.07132.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

Review 1.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

2.  Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Authors:  Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

3.  Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.

Authors:  Thomas F Chromecki; Behfar Ehdaie; Giacomo Novara; Karl Pummer; Richard Zigeuner; Christian Seitz; Armin Pycha; Richard K Lee; Eugene K Cha; Pierre I Karakiewicz; Casey Ng; Jay D Raman; Felix K Chun; Hans-Martin Fritsche; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Patrick J Bastian; Juan I Martínez-Salamanca; Douglas S Scherr; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-04-17       Impact factor: 4.226

Review 4.  Bladder cancer in the elderly.

Authors:  Shahrokh F Shariat; Matthew Milowsky; Michael J Droller
Journal:  Urol Oncol       Date:  2009 Nov-Dec       Impact factor: 3.498

Review 5.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

Review 6.  Impact of gender on bladder cancer incidence, staging, and prognosis.

Authors:  Harun Fajkovic; Joshua A Halpern; Eugene K Cha; Atessa Bahadori; Thomas F Chromecki; Pierre I Karakiewicz; Eckart Breinl; Axel S Merseburger; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-06-09       Impact factor: 4.226

Review 7.  Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.

Authors:  Rosa Nadal; Andrea B Apolo
Journal:  Curr Treat Options Oncol       Date:  2018-05-28

Review 8.  Contemporary update on neoadjuvant therapy for bladder cancer.

Authors:  Daniel P Nguyen; George N Thalmann
Journal:  Nat Rev Urol       Date:  2017-03-14       Impact factor: 14.432

9.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

10.  [Neoadjuvant, inductive or adjuvant chemotherapy of bladder cancer].

Authors:  C-H Ohlmann; M De Santis
Journal:  Urologe A       Date:  2013-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.